Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Stage 4 Metastatic NSCLC

Carcinoma, Non-Small-Cell Lung Clinical Trial

Official title:

Phase 1 Trial Evaluating the Safety and Tolerability of Gamma Delta T-Cell Infusions in Combination With Low Dose Radiotherapy in Subjects With Stage 4 Metastatic Non-Small Cell Lung Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06069570
• Other study ID #: DELTACEL-01
• Status: Recruiting
• Phase: Phase 1
• Start date: November 7, 2023
• Est. completion date: January 2027

Study information

• Verified date: September 2023
• Source: Kiromic BioPharma Inc.
• Contact: Rose Marie Cavanna-Mast, CCRA
• Phone: 1-844-539-2873
• Email: rcavannamast[@]kiromic.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a clinical trial studying intravenous infusions of allogeneic gamma delta T cells after receiving low dose radiotherapy in participants with metastatic non-small cell lung cancer to evaluate the safety and efficacy of combining immunotherapy with radiation therapy.

Description:

In this clinical trial, or 'study', participants with stage 4, non-small cell cancer (NSCLC), will receive KB-GDT-01, an allogeneic (cells from healthy donors) gamma delta T-cell product. All participants will receive KB-GDT-01 as intravenous infusions in combination with radiotherapy. After being informed about the study and its potential risks, during the 28-day screening period, all consented participants will have laboratory tests, assessments, tumor scans, and a tumor biopsy. Cytokine release syndrome symptoms and other potential adverse effects, will be monitored during the dose limiting toxicity period. The study will be conducted in 2 parts, with the same number of visits in each part. In Part 1 Dose Escalation, the study will attempt to identify the best dose with the lowest incidence of adverse effects (AE) and try to identify if the KB-GDT-01 is working (effectiveness). In Part 2 Dose Expansion the best dose will be further investigated for AE and effectiveness. There will be up to 36 participants in Part 1 and up to 12 additional participants in Part 2 of the study. The total treatment cycle of the study drug protocol will be completed in 10 days. Participants will then attend clinic visits during a 30-day short-term follow-up period, with a subsequent long-term follow-up period up to Month 24

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 48
• Est. completion date: January 2027
• Est. primary completion date: October 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Signed and dated informed consent form.
• Male or female, > 18 years old.
• Minimum body weight of 50 kilograms (kg).
• Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
• Histologically or cytologically confirmed stage 4 metastatic NSCLC
• Progressed on at least 2 lines of SOC therapy including platinum-based chemotherapy and immune checkpoint inhibitors.
• Genomic screening, with tumors with known actionable molecular alterations, such as EGFR, ALK, ROS-1, BRAF, RET, MET, and KRAS etc., must have progressed on appropriate target-directed molecular therapy.
• At least one measurable target lesion based on RECIST v1.1
• All toxicity associated with previous treatments are recovered to CTCAE grade of =1, except for continuing alopecia.
• Life expectancy of at least 6 months.
• Adequate hematopoietic, hepatic and renal function
• Agree to adequate contraception for up to 120 days after the last dose of study drug.
• Negative serum pregnancy test for women of childbearing potential

Exclusion Criteria:

• Chemotherapy, investigational, and/or check-point inhibitor therapy within the 30 days prior to study Day 1.
• Major surgery, except for vascular access placement, within the 30 days prior to study Day 1.
• Active autoimmune disease requiring immunosuppressive therapy.
• Infection requiring systemic treatment within 30 days prior to study Day 1.
• History of peritoneal effusion (ascites), pericardial, or pleural effusions/nodules.
• Uncontrolled hypertension, history of arrhythmia including atrial fibrillation, unstable angina, decompensated congestive heart failure, cardiac ejection fraction = 50%, myocardial infarction, or marked baseline prolonged QT/QTc intervals.
• Human immunodeficiency virus (HIV), Hepatitis B, or Hepatitis C detection.
• Participation in the treatment portion of a clinical trial or completed a clinical trial within the 30 days prior to the first dose of KB-GDT-01.
• Presence of any condition that may, in the opinion of the Investigator, render the patient inappropriate from participating in the study.
• Breastfeeding or pregnant female, or patient is expecting to conceive or father children during the study.
• Allergy or intolerance to any of the study product ingredients or excipients.
• Live vaccines administered within 30 days prior to study Day 1.

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung

Intervention

Biological:
• KB-GDT-01
KB-GDT-01 is an allogeneic, gamma delta T-cell suspension product manufactured from the isolation of healthy donor peripheral blood mononuclear cells (PBMC). The KB-GDT-01 cells are cryopreserved in vapor phase liquid nitrogen (LN2) in 50 mL CryoMACS® cryobags for a total of 200 × 106 viable cells/bag. The KB-GDT-01 cryopreserved product is thawed and administered intravenously (IV) until the entire bag is infused by gravity. Low dose radiotherapy (LDRT) will be administered to selected tumor sites (maximum of 5 isocenters) at 1.0 Gy/fraction on Days 1 and 2, followed by the KB-GDT-01 IV infusion on Day 3. LDRT will be repeated on Days 8 and 9, and the 2nd KB-GDT-01 IV infusion on Day 10.

Locations

Country	Name	City	State
United States	Beverly Hills Cancer Center & Optima Diagnostic Imaging	Beverly Hills	California
United States	University of Pittsburgh School of Medicine	Pittsburgh	Pennsylvania

Sponsors (3)

Lead Sponsor	Collaborator
Kiromic BioPharma Inc.	Statistics & Data Corporation, Stiris Research Inc

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with Adverse Events (AE) and/or Dose Limiting Toxicities (DLT) as a Measurement of Safety and Tolerability of KB-GDT-01 in Combination with LDRT	DLT, defined as the occurrence or start of a clinically significant Grade 3 or greater AE (per CTCAE v5.0) occurring during the DLT assessment period that cannot be attributed to disease progression, intercurrent illness, or concomitant medication.	From the first infusion of study drug until Day 40 or 30 days after the last study drug infusion, whichever occurs later
Secondary	Objective Response Rate (ORR)	Investigator assessed ORR per RECIST v1.1. ORR is defined as the percentage of participants with a best overall response of complete or partial response.	From first study drug infusion through to Month 24
Secondary	Progression Free Survival (PFS)	Investigator assessed PFS per RECIST v1.1. PFS is defined as the time from first study drug infusion until the first evidence of disease progression or death.	From first study drug infusion until the first evidence of disease progression, death or Month 24.
Secondary	Overall Survival (OS)	Investigator assessed OS per RECIST v1.1. OS is defined as the time from first study drug infusion to death.	From first study drug infusion until death or Month 24.
Secondary	Time to Progression (TTP)	Investigator assessed TTP per RECIST v1.1. TTP is defined as the time from first study drug infusion until first evidence of disease progression.	From first study drug infusion until first evidence of disease progression or Month 24.
Secondary	Time to Treatment Response (TTR)	Investigator assessed TTR per RECIST v1.1. TTR is defined as the time from first study drug infusion until first evidence of disease response.	From first study drug infusion until first evidence of disease response or Month 24.
Secondary	Disease Control Rate (DCR)	Investigator assessed DCR per RECIST v1.1 DCR is defined as the percentage of participants with complete response, partial response or stable disease.	From first study drug infusion until first evidence of disease response or stable disease or Month 24.